Identifying MicroRNA Biomarkers of Obesity-Associated Renal Disease after Living Kidney Donation

Identifying MicroRNA Biomarkers of Obesity-Associated Renal Disease after Living Kidney Donation - MicroRNA Biomarker of Obesity-Associated Renal disease

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON39270

Enrollment

650

Registered

2013-08-02

Start date

2014-05-01

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obesitas Kidneyfailure Obesity-Associated Renal Disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: All former living kidney donors who donated a kidney since 1968 at the Leiden University Medical Center (aproximate n

Exclusion criteria

Exclusion criteria: Patients will be excluded from analyses if their medical history or the oral glucose tolerance test (OGTT) at the day of assessment reveals presence of diabetes mellitus.

Design outcomes

Primary

Measure	Time frame
The main outcome parameter will be a top-5 of differentially expressed miRs in plasma and urine between obese progressors to albuminuria versus non-progressors, adjusted for miRs associated with progression to albuminuria not related to obesity.	—

Secondary

Measure	Time frame
- albuminuria from 24h urine - renal function as assessed by 24h urinary creatinine clearance - anthropometric measures of obesity (BMI, waist/hip ratio) - fasting glucose and post OGTT glucose - automated blood pressure (dynamap) - non-invasive assessment of microcirculation using orthogonal polarization spectral (OPS) imaging of oral mucosa. - serum/plasma parameters of obesity-associated parameters of inflammation (hsCRP), endothelial dysfunction (sICAM-1, sVCAM-1, sE-Selectine) and coagulation (PA1-1) - smoking history, alcohol use - medication including hormonal replacement therapy in women - medical history / record review for cardiovascular history and/or de novo renal disease.	—

Measure

Time frame

- albuminuria from 24h urine - renal function as assessed by 24h urinary creatinine clearance - anthropometric measures of obesity (BMI, waist/hip ratio) - fasting glucose and post OGTT glucose - automated blood pressure (dynamap) - non-invasive assessment of microcirculation using orthogonal polarization spectral (OPS) imaging of oral mucosa. - serum/plasma parameters of obesity-associated parameters of inflammation (hsCRP), endothelial dysfunction (sICAM-1, sVCAM-1, sE-Selectine) and coagulation (PA1-1) - smoking history, alcohol use - medication including hormonal replacement therapy in women - medical history / record review for cardiovascular history and/or de novo renal disease.

—

Countries

Netherlands

Outcome results